About Aptose Biosciences
Aptose Biosciences is a company based in Mississauga (Canada) founded in 1986 was acquired by Hanmi Pharmaceuticals in November 2025. It operates as a HealthTech. The company has 13 employees as of December 31, 2024. Aptose Biosciences offers products and services including Tuspetinib, Luxeptinib (B-NHL), and Luxeptinib (AML/MDS).
- Headquarter Mississauga, Canada
- Employees 13 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aptose Biosciences. Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-24.21 M53.57as on Dec 31, 2024
-
EBITDA
$-24.61 M53.42as on Dec 31, 2024
-
Latest Funding Round
$9.7 M (USD), Post-IPO
Jan 31, 2024
- Investors
-
Employee Count
13
as on Dec 31, 2024
-
Acquired by
Hanmi Pharmaceuticals
(Nov 19, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Aptose Biosciences
Aptose Biosciences is a publicly listed company on the OTC with ticker symbol APTOF in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Aptose Biosciences
Aptose Biosciences offers a comprehensive portfolio of products and services, including Tuspetinib, Luxeptinib (B-NHL), and Luxeptinib (AML/MDS). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Tuspetinib is developed for treating myeloid malignancies like AML.
Luxeptinib is formulated for B-cell malignancies including CLL, NHL.
Luxeptinib targets myeloid malignancies such as AML and MDS.
Unlock access to complete
Funding Insights of Aptose Biosciences
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $9.7M
-
First Round
First Round
(31 May 2012)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2024 | Amount | Post-IPO - Aptose Biosciences | Valuation |
investors |
|
| Apr, 2014 | Amount | Post-IPO - Aptose Biosciences | Valuation |
investors |
|
| Dec, 2013 | Amount | Post-IPO - Aptose Biosciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aptose Biosciences
Aptose Biosciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Hanmi. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
NCEs and generic pharmaceutical products are developed and manufactured.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aptose Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aptose Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aptose Biosciences Comparisons
Competitors of Aptose Biosciences
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aptose Biosciences
Frequently Asked Questions about Aptose Biosciences
When was Aptose Biosciences founded?
Aptose Biosciences was founded in 1986 and raised its 1st funding round 26 years after it was founded.
Where is Aptose Biosciences located?
Aptose Biosciences is headquartered in Mississauga, Canada. It is registered at Mississauga, Ontario, Canada.
How many employees does Aptose Biosciences have?
As of Dec 31, 2024, the latest employee count at Aptose Biosciences is 13.
What does Aptose Biosciences do?
Aptose Biosciences is engaged in developing precision medicines for oncology, with a primary focus on hematology. The company is involved in creating small molecule cancer therapeutics designed for single agent efficacy and to complement other anti-cancer therapies without overlapping toxicities. Their pipeline includes products targeting myeloid and lymphoid malignancies such as AML, CLL, NHL, and MDS. Clinical trials are conducted to address unmet needs in these areas, covering multiple indications within the hematology spectrum.
What products or services does Aptose Biosciences offer?
Aptose Biosciences offers Tuspetinib, Luxeptinib (B-NHL), and Luxeptinib (AML/MDS).
Is Aptose Biosciences publicly traded?
Yes, Aptose Biosciences is publicly traded on OTC under the ticker symbol APTOF.
Who are Aptose Biosciences's investors?
Aptose Biosciences has 1 investor. Key investors include Hanmi.
What is Aptose Biosciences's ticker symbol?
The ticker symbol of Aptose Biosciences is APTOF on OTC.